| ［1］ |
Lindauer M, Hochhaus A. Dasatinib［J］. Recent Results Cancer Res, 2018,212:29⁃68. doi: 10.1007/978⁃3⁃319⁃91439⁃8_2.
|
| ［2］ |
Drucker AM, Wu S, Busam KJ, et al. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta⁃analysis and clinical characterization［J］. Eur J Haematol, 2013,90（2）:142⁃150. doi: 10.1111/ejh.12052.
|
| ［3］ |
Tarantini F, Anelli L, Ingravallo G, et al. Skin lesions in chronic myeloid leukemia patients during dasatinib treatment［J］. Cancer Manag Res, 2019,11:7991⁃7996. doi: 10.2147/CMAR.S217872.
|
| ［4］ |
Wang JF, Orlow SJ. Keratosis pilaris and its subtypes: associations, new molecular and pharmacologic etiologies, and therapeutic options［J］. Am J Clin Dermatol, 2018,19（5）:733⁃757. doi: 10.1007/s40257⁃018⁃0368⁃3.
|
| ［5］ |
Oro⁃Ayude M, Feito M, Quintana⁃Castanedo L, et al. Keratosis pilaris⁃like eruption secondary to nilotinib in a child［J］. Pediatr Dermatol, 2020,37（5）:968⁃969. doi: 10.1111/pde.14267.
|
| ［6］ |
Patel AB, Solomon AR, Mauro MJ, et al. Unique cutaneous reaction to second⁃ and third⁃generation tyrosine kinase inhibitors for chronic myeloid leukemia［J］. Dermatology, 2016,232（1）:122⁃125. doi: 10.1159/000437383.
|
| ［7］ |
Okereke UR, Colozza S, Cohen DE. A case of new onset keratosis pilaris after discontinuation of erlotinib［J］. J Drugs Dermatol, 2014,13（11）:1410⁃1411.
|
| ［8］ |
Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF⁃mutant melanoma （COLUMBUS）: a multicentre, open⁃label, randomised phase 3 trial［J］. Lancet Oncol, 2018,19（5）:603⁃615.doi:10.1016/S1470⁃2045（18）30142⁃6.
|
